INVEGA® (paliperidone) extended-release tablets are indicated for the treatment of schizophrenia in adults and adolescents (12-17 years of age). The efficacy of INVEGA® in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (12-17 years of age), as well as one maintenance trial in adults.
INVEGA® (paliperidone) extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressant therapy in adults. The efficacy of INVEGA® in schizoaffective disorder was established in two 6-week trials in adults.
Please discuss your symptoms with your healthcare professional. Your healthcare professional will review your symptoms and may consult the established guidelines, which are available in the Diagnostic and Statistical Manual of Mental Disorders, where applicable.
People with the depressive subtype of schizoaffective disorder exclusively experience depressive episodes, which include:
Feelings of sadness or emptiness
Tearfulness
Weight loss or change in appetite
Too little or too much sleep
Restlessness
Feeling tired or lack of energy
Guilt or self-blame
Loss of concentration or the ability to make decisions
Loss of interest or pleasure in activities that were once enjoyed
Thoughts of death or suicide
People with the bipolar subtype of schizoaffective disorder experience manic or mixed episodes (and may or may not also experience depressive episodes). Manic mood symptoms include:
Unusually high, grand, or irritable mood
Inflated self-esteem
Decreased need for sleep
More talkative than usual
Racing thoughts or ideas
Easily distracted
An increase in working towards goals (especially in creative work)
Risky behavior (such as gambling or sex with many partners)
Please talk to your doctor or healthcare professional if you have questions about schizoaffective disorder.
